Physician profile
Robert Staszewski
NPI 1891785168
$2,657.87
in general payments reported to CMS, 2019-2025
15 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2021: $24.62 · 2022: $14.48 · 2023: $320 · 2024: $685 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,442.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $675.28 | 2021-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $314.55 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $282.96 | 2023-2025 | |
| Incyte Corporation | $261.10 | 2024-2025 | Opzelura, Opzelura |
| Ucb, INC. | $241.60 | 2025 | Bimzelx |
| Organon LLC | $218.03 | 2025 | Vtama, Nexplanon |
| Lilly USA, LLC | $137.19 | 2023-2025 | Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $136.62 | 2024-2025 | Nemluvio, Aklief, Oracea |
| Leo Pharma INC. | $118.66 | 2019-2022 | |
| Amgen INC. | $78.64 | 2024-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $74.43 | 2024 | Sotyktu |
| Dermavant Sciences, INC. | $46.42 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $25.71 | 2019 | |
| Genzyme Corporation | $24.98 | 2019 | |
| Almirall LLC | $21.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Staszewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.